{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:48:53Z","timestamp":1782193733797,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"none"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SGLT2 inhibitors reduce urinary protein and slow eGFR decline in clinical trials.\u00a0However, real-world evidence on within-patient changes in eGFR slope before and after treatment initiation, and their relationship to changes in urinary protein, remains limited.\u00a0This study was designed to address these concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 90 Japanese CKD patients who initiated dapagliflozin and had\u2009\u2265\u20095 eGFR measurements during both the 12-month periods before and after initiation.\u00a0The treatment effect was defined as the\u00a0\u0394eGFR slope (post-minus pre-initiation slope).\u00a0Clinical factors associated with\u00a0\u0394eGFR slope were assessed using multivariable regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean eGFR slope significantly improved from\u2009\u2212\u20095.12\u2009\u00b1\u20095.93\u00a0to\u00a01.59\u2009\u00b1\u20095.27\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      \/year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\u00a0Urinary protein decreased modestly without statistical significance (median\u00a00.65\u2009\u2212\u20090.55\u00a0g\/gCr,\u00a0\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.155).\u00a0Significant improvements in eGFR slope were observed regardless of baseline urinary protein level or the reduction rate.\u00a0Multivariable analysis revealed that a reduction in serum uric acid (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u2009\u2212\u20090.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but not urinary protein, was independently associated with the\u00a0\u0394eGFR slope.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin significantly improves the eGFR slope,\u00a0which was not statistically associated with urinary protein changes in this cohort, in routine clinical practice.\u00a0These findings underscore the clinical value of eGFR slope-based evaluation for monitoring individualized therapeutic responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02860-7","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:27:54Z","timestamp":1776097674000},"page":"1056-1065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["eGFR slope improvement with SGLT2 inhibitors is not statistically associated with changes in urinary protein in Japanese CKD patients: a single-center real-world analysis"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6590-7797","authenticated-orcid":false,"given":"Shogo","family":"Kuwagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Chin-Kanasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahomi","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Imamura-Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yamahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Yasuda-Yamahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tanaka-Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"24","key":"2860_CR1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"2860_CR2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"2860_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"issue":"4S","key":"2860_CR4","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"6","key":"2860_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, et al. GFR decline as an end point for clinical trials in chronic kidney disease. Am J Kidney Dis. 2014;64(6):821\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2860_CR6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735\u201345.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2860_CR7","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1681\/ASN.2019010009","volume":"30","author":"T Greene","year":"2019","unstructured":"Greene T, Ying J, Vonesh EF, et al. Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. J Am Soc Nephrol. 2019;30(9):1756\u201369.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2860_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.kint.2024.08.019","volume":"106","author":"S Miyamoto","year":"2024","unstructured":"CANPIONE study Investigators, Miyamoto S, et al. A randomized, open-label clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney Int. 2024;106(5):972\u201384.","journal-title":"Kidney Int"},{"issue":"11","key":"2860_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2860_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2860_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2860_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2860_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. 2026;335:233\u201344.","journal-title":"JAMA"},{"issue":"3","key":"2860_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004115","volume":"12","author":"K Kitaoka","year":"2024","unstructured":"Kitaoka K, et al. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease: a real-world cohort study. BMJ Open Diabetes Res Care. 2024;12(3):e004115.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"2860_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.ekir.2025.04.042","volume":"10","author":"H Ueda","year":"2025","unstructured":"Ueda H, Tsuboi N, et al. Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy. Kidney Int Rep. 2025;10(7):2405\u201313.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"2860_CR16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","volume":"39","author":"C Wanner","year":"2024","unstructured":"Wanner C, Nangaku M, et al. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrol Dial Transplant. 2024;39(9):1504\u201313.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02860-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:40:27Z","timestamp":1782193227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02860-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2860"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02860-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective observational study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the ethics committee of Shiga University of Medical Science (Approval No. R2024-073). No animal studies were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Because of the retrospective nature of the study and the use of anonymized clinical data, the requirement for written informed consent was waived in accordance with institutional and national regulations. An opt-out approach was applied.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}